Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.49 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.95 |
| ▸ | IDO1 | P14902 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28059156 | 0.98 | LOXL2 (0.91) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| Methane SCHEMBL29190749 | 0.98 | LOXL2 (0.91) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL354332 | 0.98 | LOXL2 (1.00) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| Methane SCHEMBL11552193 | 0.95 | LOXL2 (0.95) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| Bromide SCHEMBL31513716 | 0.95 | LOXL2 (0.95) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL4687550 | 0.91 | LOXL2 (0.88) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL11816242 | 0.88 | LOXL2 (0.81) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| Phosphonic Acid SCHEMBL27895241 | 0.88 | LOXL2 (0.81) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| Benzylamine SCHEMBL27935312 | 0.87 | LOXL2 (0.80) | LOXL2IDO1ALDH1A1CYP2C19MEN1 | |
| SCHEMBL12635614 | 0.86 | LOXL2 (0.78) | LOXL2IDO1TSHRALDH1A1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| US-4301196-A | USING ACCELERATING OR DEPOLARIZING AGENTS WHICH ARE ORGANONITROGEN COMBOUNDS | KOLLMORGEN TECHNOLOGIES CORP. (US) | 1981-11-17 | — | — | US | claimed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2024246857-A1 | UREA COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ASTHMA AND PARKINSON'S DISEASE | INNOPHARMASCREEN INC. (KR) | 2024-12-05 | — | — | WO | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-10-31 | — | — | US | disclosed |
| CN-114315862-B | Method for preparing penicillin sulfoxide ester by continuous flow | 沈阳化工研究院有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-114437110-B | Application of supported catalyst in continuous preparation of penicillin sulfoxide ester | 沈阳化工研究院有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-4820843-A | Tetrazole intermediates to antihypertensive compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0291969-A2 | Tetrazole intermediates to antihypertensive compounds | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
| US-4741900-A | Antibody-metal ion complexes | CYTOGEN CORPORATION (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4622217-A | I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1986-11-11 | — | — | US | disclosed |
| US-4548904-A | FORMING REACTION PRODUCT OF PROTEIN AND REAGENT, DEGRADATION TO REMOVE TERMINAL AMINO ACID, THEN CHROMATOGRAPHY ANALYSIS | MOLECULAR GENETICS RESEARCH & DEVELOPMENT (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0113538-A2 | Protein sequencing method and reagent | MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP (US) | 1984-07-18 | — | — | EP | disclosed |
| US-4301196-A | USING ACCELERATING OR DEPOLARIZING AGENTS WHICH ARE ORGANONITROGEN COMBOUNDS | KOLLMORGEN TECHNOLOGIES CORP. (US) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CA2 2580/4885KCNH2 845/4885ACHE 4528/4885 |
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | CBR1, CBR3, PPIC | CA2 239/4885KCNH2 2338/4885ACHE 4422/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | CA2 2580/4885KCNH2 845/4885ACHE 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.